Mode
Text Size
Log in / Sign up

C-reactive protein testing impacts antibiotic prescribing rates in acute COPD exacerbationsBlood tests may help doctors decide when to use antibiotics

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
CRP point-of-care testing significantly reduces antibiotic prescriptions in primary care for acute COPD exacerbations.

A meta-analysis evaluated the impact of using C-reactive protein (CRP) point-of-care testing versus clinical assessment alone in managing acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The study aimed to determine if these biomarkers could refine prescribing practices in primary care settings.

Results indicated that utilizing CRP tests led to a statistically significant reduction in antibiotic prescriptions, with an odds ratio of 0.41. While the evidence for this specific outcome was noted as having low certainty, the data suggests a measurable shift in clinical decision-making when these biomarkers are integrated into standard protocols.

In contrast, there was insufficient data available to draw firm conclusions regarding procalcitonin (PCT) laboratory tests for antibiotic prescribing. The study highlights the potential of CRP as a practical tool for clinicians, despite the limitations in current evidence certainty and the lack of conclusive data for alternative biomarkers.

Living with chronic obstructive pulmonary disease (COPD) is hard enough, but sudden flare-ups make things even more difficult. When these episodes happen, doctors often have to decide quickly if the patient needs antibiotics to fight an infection. This decision can be tough because many people do not actually need antibiotics for every flare-up.

A review of several studies looked at using a blood test called C-reactive protein (CRP) to help guide this choice. The results showed that when doctors used this specific test, they prescribed fewer antibiotics than they did with clinical assessment alone. However, the researchers noted that the evidence for this finding is currently not very certain.

Another common blood test, procalcitonin (PCT), was also looked at, but there was not enough data to reach a clear conclusion about its use. While the CRP test showed promise in reducing antibiotic use, it is still early days and more high-quality evidence is needed to know exactly how much it can change daily care.

What this means for you:
A specific blood test (CRP) may help doctors reduce unnecessary antibiotic use for lung disease flare-ups.

Common questions

How does the CRP blood test help with lung disease?

The C-reactive protein (CRP) test is a point-of-care test that helps doctors decide if a patient needs antibiotics during a flare-up of chronic obstructive pulmonary disease. In this study, using the CRP test led to a significant reduction in antibiotic prescribing compared to clinical assessment alone.

Is the evidence for using these blood tests reliable?

The researchers noted that the evidence for using the CRP test is currently of low certainty. While it showed a reduction in antibiotic use, more high-quality data is needed to confirm how reliably it can guide treatment decisions.

What about the procalcitonin (PCT) blood test?

While researchers looked at the procalcitonin (PCT) blood test as well, there was not enough data available to draw any firm conclusions about whether it helps doctors decide on antibiotic use for lung disease.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are frequently treated with antibiotics in primary care, leading to antibiotic resistance and adverse effects. Assessing biomarkers might assist in reducing unnecessary antibiotic prescribing when used alongside clinical assessment. AIM: To evaluate the benefit of reviewing biomarkers in point-of-care testing (POCT) within practices and through laboratory blood tests in efforts to decrease antibiotic prescribing for AECOPD. DESIGN AND SETTING: Systematic review of randomised controlled trials (RCTs) and non-randomised studies conducted in primary care from January 2022 to November 2025 assessing POCTs for chronic obstructive pulmonary disease (COPD). METHOD: The primary outcome was the rate of antibiotic prescribing or use, and secondary outcomes were biomarker thresholds for prescribing antibiotics and patient harm. Searches were conducted in four medical databases, six registers, and COPD academic societies. Data were extracted and assessed for quality and bias. A meta-analysis was performed whenever possible. RESULTS: A total of seven studies were included: one RCT and four non-randomised studies for C-reactive protein (CRP) POCT; and two RCTs on procalcitonin (PCT) in laboratories. The meta-analysis of CRP POCT indicated a statistically significant reduction in antibiotic prescribing (odds ratio 0.41, 95% confidence interval = 0.32 to 0.53; ² = 36%; low certainty of evidence). No meta-analysis for PCT was feasible. CONCLUSION: CRP POCT reduced antibiotic prescribing for AECOPD in primary care settings when used alongside clinical assessment. There were insufficient data to draw conclusions about the PCT biomarker.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.